1 / 2
High-Quality China Cargrilintide CAS 1415456-99-3 - Top Suppliers and Trusted Factory for Quality Peptide Production Manufacturer, Service
Product Description
Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.
Mechanism & Efficacy
Cagrilintide is a long‑acting synthetic analogue of the pancreatic hormone amylin, classified as an amylin receptor agonist. It targets amylin receptors and related pathways that regulate appetite, satiety, gastric emptying, and post‑meal glucose metabolism. By activating these pathways, Cagrilintide helps reduce food intake, prolong feelings of fullness, and support metabolic balance in research settings. It is also being studied in combination with GLP‑1 receptor agonists such as semaglutide for enhanced weight‑loss and metabolic effects.
Dosage & Research Use
Cagrilintide is evaluated primarily in clinical and preclinical research for metabolic and obesity studies. In major clinical programs such as the Phase 2 and Phase 3 “REDEFINE” trials, cagrilintide has been administered as a subcutaneous injection once weekly with a gradual dose escalation protocol to minimize gastrointestinal side effects. Target doses in these protocols frequently reached 2.4 mg per week, with initial titration starting from lower doses such as 0.3–0.5 mg during the first weeks of treatment.
Frequently Asked Questions
Q1
What is Cagrilintide?
Cagrilintide is a long-acting synthetic analogue of the pancreatic hormone amylin. It is classified as an amylin receptor agonist and is primarily used in metabolic and obesity research.
Q2
How does Cagrilintide promote weight loss?
It targets amylin receptors to regulate appetite, enhance satiety, slow gastric emptying, and improve post-meal glucose metabolism, which together help reduce food intake and prolong feelings of fullness.
Q3
Is Cagrilintide used alone or with other medications?
While it has its own distinct mechanism, it is currently being heavily researched and developed in combination with GLP-1 receptor agonists, such as semaglutide, to achieve enhanced and sustained weight loss.
Q4
How is Cagrilintide administered in clinical trials?
In major clinical programs like the "REDEFINE" trials, it is administered as a once-weekly subcutaneous injection.
Q5
What is the typical target dosage for Cagrilintide?
Research protocols frequently aim for a target dose of 2.4 mg per week, following an initial titration phase.
Q6
Why is a gradual dose escalation protocol used?
A gradual dose escalation, starting from lower doses like 0.3–0.5 mg during the first few weeks, is utilized to minimize potential gastrointestinal side effects.
